<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> of resting primary human B cells by Epstein-Barr virus (EBV) results in their transformation into indefinitely proliferating lymphoblastoid cell lines (LCLs) </plain></SENT>
<SENT sid="1" pm="."><plain>LCL formation serves as a model for <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e>, and LCLs are phenotypically similar to EBV-positive diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e>), which represent a common <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>B-cell <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> by EBV induces the expression of several cellular microRNAs (miRNAs), most notably miR-155, which is overexpressed in many <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and can induce B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> when overexpressed in animals </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we demonstrate that miR-155 is the most highly expressed miRNA in LCLs and that the selective inhibition of miR-155 function specifically inhibits the growth of both LCLs and the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> cell line IBL-1 </plain></SENT>
<SENT sid="4" pm="."><plain>Cells lacking miR-155 are inefficient in progressing through S phase and spontaneously undergo <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, three other B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> lines, including two EBV-positive Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines, grew normally in the absence of miR-155 function </plain></SENT>
<SENT sid="6" pm="."><plain>These data identify the induction of cellular miR-155 expression by EBV as critical for the growth of both laboratory-generated LCLs and naturally occurring <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> and suggest that targeted inhibition of miR-155 function could represent a novel approach to the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> in vivo </plain></SENT>
</text></document>